Long-term outcomes with obeticholic acid in primary biliary cholangitis: reassuring, but still an itch we need to scratch

Affiliations

¹ Division of Gastroenterology & Hepatology, Medicine, Mayo Clinic, Rochester, MN, USA.
² Division of Gastroenterology & Hepatology, Medicine, Mayo Clinic, Rochester, MN, USA; Division of Physiology, Mayo Clinic, Rochester, MN, USA. Electronic address: gores.gregory@mayo.edu.

Comment

John E Eaton et al. Lancet Gastroenterol Hepatol. 2019 Jun.

. 2019 Jun;4(6):417-418.

doi: 10.1016/S2468-1253(19)30084-6. Epub 2019 Mar 26.

¹ Division of Gastroenterology & Hepatology, Medicine, Mayo Clinic, Rochester, MN, USA.
² Division of Gastroenterology & Hepatology, Medicine, Mayo Clinic, Rochester, MN, USA; Division of Physiology, Mayo Clinic, Rochester, MN, USA. Electronic address: gores.gregory@mayo.edu.

No abstract available

Comment on

Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study.
Trauner M, Nevens F, Shiffman ML, Drenth JPH, Bowlus CL, Vargas V, Andreone P, Hirschfield GM, Pencek R, Malecha ES, MacConell L, Shapiro D. Trauner M, et al. Lancet Gastroenterol Hepatol. 2019 Jun;4(6):445-453. doi: 10.1016/S2468-1253(19)30094-9. Epub 2019 Mar 26. Lancet Gastroenterol Hepatol. 2019. PMID: 30922873 Clinical Trial.